Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combined Phase 1 and 1/2a Clinical Trial Evaluating the Safety and Efficacy of an Autologous Muscle Stem Cell Therapy in the Treatment of Urinary Incontinence in Isolated Epispadias

Next Previous
Search
Trial Profile

Combined Phase 1 and 1/2a Clinical Trial Evaluating the Safety and Efficacy of an Autologous Muscle Stem Cell Therapy in the Treatment of Urinary Incontinence in Isolated Epispadias

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous stem cell therapy (Primary)
  • Indications Urinary incontinence
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MUST

    • Most Recent Events

    • 02 Aug 2023 Planned initiation date changed from 1 May 2023 to 1 Jun 2024.
    • 14 Jul 2023 New trial record
    • 10 Jul 2023 According to a Myopax media release, the study has received funding from the German Federal Ministry of Education and Research and the ForTra gGmbH of the Else-Kroner-Fresenius Foundation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top